Lancet trial: new scan can detect endometriosis without surgery

Oxford, April 29. The DETECT Phase 2 trial published in The Lancet Obstetrics, Gynaecology & Women's Health in April-May 2026 has demonstrated a transformative advance in endometriosis diagnosis.

A new gamma-emitting radiotracer

The study used 99mTc-maraciclatide, a gamma-emitting radiotracer. It binds to alpha-v beta-3 integrin, which is upregulated during new blood-vessel formation — a key biological signature of endometriosis.

84% accuracy

The imaging signal agreed with intraoperative diagnosis or exclusion of endometriosis in 16 of 19 participants (84%), with no false positives. This is better accuracy than any other non-invasive technique today.

Why it is revolutionary

Endometriosis confirmation typically requires laparoscopic surgery today, often delaying diagnosis by 7-10 years. The new scan could eliminate the need for surgery — a major breakthrough in women's health.

Endometriosis in 10% of women

According to the WHO, about 10% of women of reproductive age — roughly 190 million globally — have endometriosis. It causes severe pain, infertility, and affects quality of life.

FDA Fast Track

The agent has FDA Fast Track Designation. Phase 3 multi-centre international studies are due to start later in 2026, involving leading hospitals in the US, UK, Germany, and India.

Access in India

The Indian Council of Medical Research (ICMR) has signalled potential partnership with the UK researchers. AIIMS Delhi has expressed intent to become a clinical trial site in 2027.